Comparative Pharmacology
Head-to-head clinical analysis: FONDAPARINUX SODIUM versus HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FONDAPARINUX SODIUM versus HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
FONDAPARINUX SODIUM vs HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fondaparinux is a synthetic pentasaccharide that selectively binds to antithrombin III, potentiating its inhibition of factor Xa. This prevents thrombin generation and clot formation.
Heparin binds to antithrombin III (ATIII), inducing a conformational change that accelerates ATIII-mediated inhibition of coagulation factors, primarily thrombin (factor IIa) and factor Xa, thereby preventing clot formation and propagation.
2.5 mg subcutaneously once daily for prophylaxis; 5 mg (body weight <50 kg), 7.5 mg (50-100 kg), or 10 mg (>100 kg) subcutaneously once daily for treatment of venous thromboembolism
Intravenous: Initial bolus of 80 units/kg, followed by continuous infusion at 18 units/kg/hour. Titrate to achieve aPTT of 1.5-2.5 times control or anti-Xa level of 0.3-0.7 units/mL.
None Documented
None Documented
Terminal elimination half-life: 17-21 hours (young adults), 21-24 hours (elderly). Provides once-daily dosing for thromboprophylaxis.
1-2 hours (dose-dependent); extends to 2.5-4 hours with continuous infusion or renal impairment; clinical context: monitoring via aPTT required
Renal: 80-87% unchanged in urine; biliary/fecal: minimal (<10%)
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: minimal (<10%)
Category C
Category A/B
Anticoagulant
Anticoagulant